Avenzo Therapeutics completes merger with Rallybio
RLYB•Avenzo Therapeutics completed its merger with Rallybio on November 20, 2026, and the combined company will operate as Avenzo. A private placement raised approximately $215 million, and shares are expected to begin Nasdaq trading as AVZO on November 23.
1. Merger completed
Avenzo Therapeutics completed its merger with Rallybio on November 20, 2026. The combined company will operate under the Avenzo name, with shares expected to begin trading on the Nasdaq Capital Market on November 23 under the ticker AVZO.
2. Financing and ownership
A concurrent private placement raised approximately $215 million. Proceeds and existing cash are expected to fund operations into late 2028. Pre-merger Avenzo holders own 56.6% of the combined company, private placement investors 40.6% and pre-merger Rallybio holders 2.8%.
3. Cash distribution
A previously announced special cash distribution totaling $83.6 million, or $13.90 per share, is scheduled for payment on November 30.




